Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of AD-224
Condition or disease : Essential Hypertension
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AD-224A | Experimental | AD-224A+Placebo of AD-224B+Placebo of AD-224C |
|
| AD-224B | Experimental | Placebo of AD-224A+AD-224B+Placebo of AD-224C |
|
| AD-224C | Active Comparator | Placebo of AD-224A+Placebo of AD-224B+AD-224C |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-224A | Drug | PO, Once daily, 8weeks |
| |
| AD-224B |
| Measure | Description | Time Frame |
|---|---|---|
| Change rate of MSSBP | Change from baseline in mean sitting systolic blood pressure | Baseline, Week 8 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| JeongEun Park | Contact | +82-31-891-6989 | parkje@addpharma.co.kr |
| Name | Affiliation | Role |
|---|---|---|
| InHo Chae, M.D., Ph.D | Seoul National University Bundang Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Bundang Hospital | Recruiting | Seongnam-si | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
PO, Once daily, 8weeks |
|
| AD-224C | Drug | PO, Once daily, 8weeks |
|
| Placebo of AD-224A | Drug | PO, Once daily, 8weeks |
|
| Placebo of AD-224B | Drug | PO, Once daily, 8weeks |
|
| Placebo of AD-224C | Drug | PO, Once daily, 8weeks |
|